The effect of subconjunctival bevacizumab on corneal neovascularization, inflammation and re-epithelization in a rabbit model

Clinics

Volumn 66, Issue 8, 2011, Pages 1443-1449

  Mello, Glauco Reggiani ^a   Pizzolatti, Marcos Longo ^c   Wasilewski, Daniel ^b   Santhiago, Marcony R ^a   Budel, Vinícius ^b   Moreira, Hamilton ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^c Hospital de Olhos do Parana   (Brazil)

Author keywords

Antiangiogenic drugs; Cornea; Corneal neovascularization; Eye burns; Neovascularization; Pathology

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CAUSTIC AGENT; MONOCLONAL ANTIBODY; SODIUM HYDROXIDE;

ANIMAL; ARTICLE; CHEMICAL BURN; CORNEA ENDOTHELIUM; CORNEA NEOVASCULARIZATION; DISEASE MODEL; DRUG EFFECT; EYE BURN; GROWTH, DEVELOPMENT AND AGING; HOSPITALIZATION; INFLAMMATION; INTRAOCULAR DRUG ADMINISTRATION; KERATITIS; MALE; PATHOLOGY; PROSPECTIVE STUDY; RABBIT; RANDOMIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BURNS, CHEMICAL; CAUSTICS; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; ENDOTHELIUM, CORNEAL; EYE BURNS; INFLAMMATION; INJECTIONS, INTRAOCULAR; KERATITIS; MALE; PROSPECTIVE STUDIES; RABBITS; RANDOM ALLOCATION; SEVERITY OF ILLNESS INDEX; SODIUM HYDROXIDE;

EID: 80052693277     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322011000800023     Document Type: Article

References (26)

1. Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr Opin Ophthalmol. 2001;12:242-9, doi: 10.1097/00055735-200108000-00002.
2. Hill JC, Maske R. An animal model for corneal graft rejection in high-risk keratoplasty. Transplantation. 1988;46:26-30, doi: 10.1097/00007890-198807000-00003.
3. Koay PY, Lee WH, Figueiredo FC. Opinions on risk factors and management of corneal graft rejection in the United kingdom. Cornea. 2005;24:292-6, doi: 10.1097/01.ico.0000138841.44926.f8.
4. Kuckelkorn R, Schrage N, Keller G, Redbrake C. Emergency treatment of chemical and thermal eye burns. Acta Ophthalmol Scand. 2002;80:4-10, doi: 10.1034/j.1600-0420.2002.800102.x.
5. Kvanta A. Ocular angiogenesis: the role of growth factors. Acta Ophthalmol Scand. 2006;84:282-8, doi: 10.1111/j.1600-0420.2006.00659.x.
6. Papathanassiou M, Theodossiadis PG, Liarakos VS, Rouvas A, Giamarellos-Bourboulis EJ, Vergados IA. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol. 2008;145:424-31, doi: 10.1016/j.ajo.2007.11.003.
7. Tolentino MJ, Miller JW, Gragoudas ES, Chatzistefanou K, Ferrara N, Adamis AP. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol. 1996;114:964-70.
8. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci. 2000;41:2514-22.
9. Gan L, Fagerholm P, Palmblad J. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand. 2004;82:557-63, doi: 10.1111/j.1600-0420.2004.00312.x.
10. Kahook MY, Lin SC. Anti-VEGF Therapy: Next Stop, Glaucoma? Review of Ophthalmology. 2008;15:47-9.
11. Zhu Q, Ziemssen F, Henke-Fahle S, Tatar O, Szurman P, Aisenbrey S, et al. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology. 2008;115:1750-1755, 1755 e1751, doi: 10.1016/j.ophtha.2008.04.023.
12. Hosseini H, Nejabat M, Mehryar M, Yazdchi T, Sedaghat A, Noori F. Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis. Clin Experiment Ophthalmol. 2007;35:745-8, doi: 10.1111/j.1442-9071.2007.01572.x.
13. Hurmeric V, Mumcuoglu T, Erdurman C, Kurt B, Dagli O, Durukan AH. Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs. Cornea. 2008;27:357-62, doi: 10.1097/ ICO.0b013e318160d019.
14. Fechine-Jamacaru FV. Modelo de angiogênese inflamatória em córnea de coelho induzida pela cauterização alcalina pontual. Acta Cir. bras. 2005;20:64-73.
15. Li Z, Van Bergen T, Van de Veire S, Van de Vel I, Moreau H, Dewerchin M, et al. Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2009;50:5217-25, doi: 10.1167/iovs.08-2662.
16. Yoeruek E, Ziemssen F, Henke-Fahle S, Tatar O, Tura A, Grisanti S, et al. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmol. 2008;86:322-8, doi: 10.1111/j.1600-0420.2007.01049.x.
17. Saravia M, Zapata G, Ferraiolo P, Racca L, Berra A. Anti-VEGF monoclonal antibody-induced regression of corneal neovascularization and inflammation in a rabbit model of herpetic stromal keratitis. Graefes Arch Clin Exp Ophthalmol. 2009;247:1409-16, doi: 10.1007/s00417-009-1101-y.
18. Cole N, Hume EB, Jalbert I, Vijay AK, Krishnan R, Willcox MD. Effects of topical administration of 12-methyl tetradecanoic acid (12-MTA) on the development of corneal angiogenesis. Angiogenesis. 2007;10:47-54, doi:10.1007/s10456-007-9063-3.
19. Bock F, Konig Y, Kruse F, Baier M, Cursiefen C. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2008;246:281-4, doi: 10.1007/s00417-007-0684-4.
20. Kim T-im, Chung JL, Hong JP, et al. Bevacizumab application delays epithelial healing in rabbit cornea. Investigative ophthalmology & visual science. 2009;50:4653-9, doi: 10.1167/iovs.08-2805.
21. Chalam KV, Agarwal S, Brar VS, Murthy RK, Sharma RK. Evaluation of cytotoxic effects of bevacizumab on human corneal cells. Cornea. 2009;28:328-33, doi: 10.1097/ICO.0b013e31818b8be0.
22. Kang S, Chung SK. The effect of subconjuctival combined treatment of bevacizumab and triamcinolone acetonide on corneal neovascularization in rabbits. Cornea. 2010;29:192-6, doi: 10.1097/ICO.0b013e3181b1c82f.
23. Hoffart L, Matonti F, Conrath J, Daniel L, Ridings B, Masson GS, et al. Inhibition of corneal neovascularization after alkali burn: comparison of different doses of bevacizumab in monotherapy or associated with dexamethasone. Clinical & experimental ophthalmology. 2010;38:346-52, doi: 10.1111/j.1442-9071.2010.02252.x.
24. Lee HS, Chung SK. The effect of subconjunctival suramin on corneal neovascularization in rabbits. Cornea. 2010;29:86-92, doi: 10.1097/ICO. 0b013e3181ae91e3.
25. Pérez-Santonja JJ, Campos-Mollo E, Lledó-Riquelme M, Javaloy J, Alió JL. Inhibition of Corneal Neovascularization by Topical Bevacizumab (Anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF) in an Animal Model. Am J ophthalmol. 2010;150:519-528. e1, doi: 10.1016/j.ajo.2010.04.024.
26. Brown DM, Regillo CD. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol. 2007;144:627-37, doi: 10.1016/j.ajo.2007.06.039.